Assessment of Glycemic Control in Patients With Type 2 Diabetes Mellitus and Late Stage Chronic Kidney Disease

Northwell Health80 enrolled

Overview

Diabetes control is often assessed by tests of glucose levels over time, such as the glycosylated hemoglobin A1c (HbA1c) and fructosamine. In the later stages of chronic kidney disease (CKD) there is limited data available on the utility of these tests. There are reasons to believe that the tests may be less accurate in this population. Continuous glucose monitoring (CGM) offers an effective method for understanding the totality of glucose exposure and incidence of both hyperglycemic and hypoglycemic excursions.

In the proposed study Investigator plan to utilize CGM in patients with late stage CKD stages 3b-5 to 1) determine accuracy of HbA1c and serum fructosamine testing as measures of glucose control in patients with Type 2 Diabetes Mellitus (T2DM), 2) Better understand test characteristics in the late stage CKD population (correlation, linear equation, slope, Y intercept, average glucose at different HbA1c levels), 3) Develop a preliminary understanding of how test characteristics differ in late stage CKD compared to other patients with diabetes, 4) quantify time burden and number of episodes of hypoglycemia, 4) study hyperglycemic burden and 5) analyze glucose variability. The research staff will explain the study to patients that meet all inclusion criteria. Patients will get time to understand the study, review the consent document, ask questions to the PI, and then provide their consent to participate in the study. On Day 1 of the study, a CGM (Freestyle Libre) device will be placed on patients with CKD 3b-5 which will be worn for 14 consecutive days. Patients will return on Day 14 to remove the CGM device. HbA1c and fructosamine values will be drawn on Day 14 and these results will be compared with average glucose monitoring values as recorded on the CGM device. Incidence, duration, and severity of both hypoglycemic and hyperglycemic events will be analyzed. Investigators hypothesis that there will be significant variability in the serum HbA1c values when compared with calculated HbA1c from CGM readings. Investigators also hypothesize that the results will reflect a greater incidence of hypoglycemia in this population by CGM analysis.

Study Type

INTERVENTIONAL

Allocation

Purpose

PREVENTION

Conditions

Diabetes Kidney Diseases

Interventions

Continuous Glucose MonitoringDEVICE

* The FreeStyle Libre Pro Flash Glucose Monitoring System is a professional continuous glucose monitoring (CGM) device indicated for detecting trends and tracking patterns in persons (age 18 and older) with diabetes. The Freestyle Libre Pro device is FDA approved (PMA# P150021). Participants will use the FreeStyle Libre Pro Flash Glucose Monitoring device according to its approved use, on the back of the arm. * CGM monitoring will be performed on Day 1 by placing the Freestyle Libre Pro on research subjects for intended use of 14 days. * Subjects will be advised to return to the research site on Day 14 to remove the CGM device for analysis.

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * 18 years and older with ability to speak and understand English * Established diagnosis of type 2 Diabetes Mellitus * Chronic Kidney Disease (stages 3b, 4 or 5, eGFR (Glomerular Filtration Rate) \< 45 ml/min, and not on dialysis) documented within 3 months of enrollment Exclusion Criteria: * Type 2 Diabetes Mellitus. * Patient with End stage kidney disease on Dialysis. * Presence of Hemoglobinopathies. * Red blood cell transfusion in the last 12 weeks. * Hb \< 9 g/dL documented within 3 months of enrollment - Dosing with an erythropoiesis stimulating agent is acceptable but dose must be stable for two months. * Use of acetaminophen on a daily basis. * Systemic steroid treatment in the past 12 weeks. * Greater than 50% dose change in diabetes medications or new diabetes medications started in the previous 8 weeks. * Currently pregnant.

Locations (1)

Northwell Health (Division Endocrinology and Nephrology)

Great Neck, New York, United States

Outcomes

Primary Outcomes

Mean Glucose Concentration Measured by CGM

Mean glucose concentration (mg/dL) will be measured using measurements taken by CGM device.

Time frame: 14 Days

Number of Participants With Hypoglycemic Events

Hypoglycemic event will be considered when blood sugar level is \<=70 mg/dl. Detail information like time of event, number of subjects with an event, duration of event will be analyzed.

Time frame: 14 Days

Mean Number of Hypoglycemic Events Per Participant.

Total number of hypoglycemic events per subject will be calculated during the study period. Mean number of events per subject will be analyzed.

Time frame: 14 Days

Duration Hypoglycemic Events

As monitoring device measures blood glucose level numerous time, duration of hypoglycemic event will be calculated in percent time per subject based on total duration of time subject wore CGM device.

Time frame: 14 Days

Mean HbA1c

HbA1c collected at end of the participation.

Time frame: 14 Days

Secondary Outcomes

Mean Serum Fructosamine Concentration

Serum fructosamine (µmol/L) collected at the end of participation.

Time frame: 14 Days

Determination of Serum Fructosamine

Using blood glucose information measured with continuous blood glucose monitoring device, probable level of serum fructosamine (µmol/L) will be measured for each participant and mean will be analyzed.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.